View Cart  

Eli Lilly Gets Untitled Letter for Adcirca Promotions

A A
The FDA has issued an untitled letter to Eli Lilly for online direct-to-consumer marketing and two patient videos that omitted risk information and overstated the efficacy of its hypertension drug Adcirca.

To View This Article:

Login

Subscribe To Drug Industry Daily